Runda Medical issued a performance forecast on the evening of July 19, and it is expected that the net profit attributable to shareholders of listed companies will be between 195 million yuan and 215 million yuan in the first half of 2021, an increase of 83.78 million yuan to 104 million yuan compared with the same period of the previous year, an increase of 75.33% year-on-year to 93.31%.

Recently, Fosun Pharma announced that the approval of the mRNA novel coronal vaccine by the Food and Drug Administration has been basically completed, and the expert review has passed. The administrative approval stage is being stepped up at present.

On July 14, China Securities Regulatory Commission (CSRC) released the news and approved the IPO registration of Sino Biological, Inc. Sino Biological is an international reagent supplier and service provider, which specializes in recombinant protein production and antibody development.

Medix Biochemica, a global leader in critical IVD raw materials, has acquired all of the shares of Diaclone SAS ("Diaclone"). Through acquisition, Medix Biochemica broadens its portfolio of critical raw materials for the in-vitro diagnostics ("IVD") industry and expands its global network.

On July 9th, Roche Diagnostics Asia-Pacific production base and R&D center built another new manufacturing building-System Reagent Manufacturing Base. It was officially completed in Suzhou Industrial Park. The total investment in the project is 390 million yuan. In the future, the system reagent products manufactured by it will be applied to the modular instruments and pathology laboratory instruments of Roche Diagnostics' central laboratories in China and other countries in the Asia-Pacific region.

Recently, it was learned from Shanghai Fosun Pharma that Fosun Industrial (Hong Kong) Co., Ltd., a subsidiary of Fosun Pharma Holding, officially signed a sales agreement with Taiwan Semiconductor Manufacturing Company, FOXCONN, YongLin, and Zuellig Pharma, respectively, to sell a total of 10 million doses of COVID-mRNA vaccine to Zuellig Pharma, which was commissioned by TSMC, FOXCONN, and YongLin. This batch of vaccine will be donated by the buyers to disease control agencies in Taiwan for local vaccination.

On July 6, 2021, Agilent Technologies (NYSE: A) announced a strategic collaboration with GenomiCare Biotechnology in a move aimed to advance the application of the latest Next Generation Sequencing (NGS) technology into the clinical and scientific arena. More specifically, the purpose of using advanced NGS technology was to accelerate the process of development of genetic testing and related products and services, and to bring high level of clinical diagnosis and treatment of cancer in China.

Quidel has issued a recall for certain lots of its Lyra brand SARS-CoV-2 tests due to the potential for false negative results in patient samples with relatively high amounts of virus.

Global life sciences leader Cytiva has acquired Intermountain Life Sciences, a manufacturer of high-purity water, buffers, and liquid cell culture media. Cytiva will use Intermountain’s manufacturing site in Utah to rapidly boost its liquid cell culture production by millions of liters.

On June 30, Sichuan Orienter Biotechnology Co., Ltd. and InTec PRODUCTS INC. applied for the Growth Enterprise Market and was accepted by Shenzhen Stock Exchange.

The US Food and Drug Administration recently granted separate Emergency Use Authorization for molecular SARS-CoV-2 tests from Exact Sciences and BioGx, an immunoassay for detecting the virus from Bio-Rad Laboratories, and an at-home specimen collection kit from Everlywell.

NEW YORK – Qiagen said on Thursday that it has formed a global strategic alliance with Japan's Sysmex to develop and commercialize cancer companion diagnostics using Sysmex's Plasma-Safe-SeqS next-generation sequencing technology.

On the evening of June 30, it is said that Hotgen Biotech will increase by about ￥1.378 billion yuan to about ￥1.598 billion yuan, with a year-on-year increase of 70546.05% to 81808.47% ,which is Compared with the same period of last year.

Recently, South Korean idol Song Joong Ki endorsed SD BIOSENSOR, an in vitro diagnostic company, sparking heated discussions in the IVD industry.

To date, no immunological data on COVID-19 heterologous vaccination schedules in humans have been reported. We assessed the immunogenicity and reactogenicity of BNT162b2 (Comirnaty, BioNTech, Mainz, Germany) administered as second dose in participants primed with ChAdOx1-S (Vaxzevria, AstraZeneca, Oxford, UK).